Nestle investors face more turbulence after another CEO ousted

Nestle has ousted CEO Laurent Freixe, replacing him with Philipp Navratil, following an internal investigation into an undisclosed romantic relationship with a subordinate that violated company policy. This marks the second CEO change in a year for the Swiss food giant, which has seen its shares underperform European peers, losing nearly a third of their value over five years despite Freixe's tenure. The sudden leadership change adds to investor uncertainty regarding Nestle's mid-term direction, particularly as the company navigates ongoing struggles with sales volumes and a review of its underperforming businesses, potentially keeping a lid on the equity story.

Analysis

Nestle is confronting a significant governance crisis, marked by the dismissal of CEO Laurent Freixe for misconduct, which represents the second abrupt CEO change within a year. This leadership instability is compounded by the planned 2026 departure of its longstanding chairman, creating a period of unprecedented turbulence for the company. The turmoil overlays a backdrop of severe financial underperformance; the company's shares have lost nearly a third of their value over five years and have fallen 17% during Freixe's brief tenure, lagging European peers. This decline is rooted in fundamental weaknesses, including a miss on first-half sales volumes and an ongoing strategic review of its underperforming vitamins business, which could result in divestments. Analyst sentiment, as highlighted by JP Morgan, is unequivocally negative, pointing to the lack of a formal succession process as a key concern that will likely "keep a lid on the equity story." There is significant doubt that the new CEO, Philipp Navratil, can immediately pivot from his predecessor's unconvincing strategy, suggesting that near-term strategic clarity will remain elusive and investor confidence low.

Key Decisions for Investors

• Investors should exercise caution, as the compounding leadership instability introduces significant governance risk on top of the company's existing operational challenges and stock underperformance.
• Monitor for any strategic announcements from the new CEO, Philipp Navratil, paying close attention to any deviation from the prior turnaround plan, which the market has received poorly.
• Closely track fundamentals in the next earnings report, specifically sales volumes and any definitive outcomes from the strategic review of the vitamins business, as these will be critical indicators of a potential recovery.
• Given the sustained share price decline and analyst concerns, consider reducing exposure or hedging positions until there is tangible evidence of a stable management team and a coherent, effective strategy.